Intercept Pharmaceuticals Inc (ICPT)
83.03
-1.06 -1.26%
NASDAQ
Jun 18, 16:59
Delayed 2m
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 196.09M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -10.76 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -317.92M |
| Profitability | |
| Gross Profit Margin (Quarterly) | 98.90% |
| Profit Margin (Quarterly) | -172.8% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield (TTM) | Upgrade |
| Price and Valuation | |
| Market Cap | 2.702B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio (TTM) | 12.52 |
| PE Ratio (TTM) | -- |
| Price to Book Value | -- |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio (Quarterly) | Upgrade |
| Free Cash Flow (Quarterly) | -84.16M |
| Return on Equity (TTM) | Upgrade |
View All ICPT News
News
-
WireHeadlineTime (ET)
-
Yahoo06/18 08:05
-
Yahoo06/17 13:50
-
Yahoo06/14 13:21
-
Yahoo06/13 21:06
-
SA Breaking News06/13 15:59
-
Yahoo06/13 08:02
-
Yahoo06/12 18:27
-
Yahoo06/12 08:02
-
Yahoo06/11 08:58
-
Yahoo06/11 08:02
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 08/02/2019 08:30 EDT | Misc | Intercept Pharmaceuticals Inc Second Quarter Earnings Conference Call in 2019 |
| 08/02/2019 | Earnings | Intercept Pharmaceuticals Inc Second Quarter Earnings in 2019 Release |
| 06/20/2019 10:00 EDT | Misc | Intercept Pharmaceuticals Inc Annual General Meeting in 2018 |
| 05/08/2019 08:30 EDT | Misc | Intercept Pharmaceuticals Inc First Quarter Earnings Conference Call in 2019 |
| 05/08/2019 | Earnings | Intercept Pharmaceuticals Inc First Quarter Earnings in 2019 Release |
| 03/01/2019 | Misc | Intercept Pharmaceuticals Inc Annual Report in 2018 |
| 02/28/2019 08:30 EST | Misc | Intercept Pharmaceuticals Inc Fourth Quarter Earnings Conference Call in 2018 |
| 02/28/2019 | Earnings | Intercept Pharmaceuticals Inc Fourth Quarter Earnings in 2018 Release |
| 10/31/2018 08:30 EDT | Misc | Intercept Pharmaceuticals Inc Third Quarter Earnings Conference Call in 2018 |
| 10/31/2018 | Earnings | Intercept Pharmaceuticals Inc Third Quarter Earnings in 2018 Release |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: https://www.interceptpharma.com
- Investor Relations URL: http://ir.interceptpharma.com/index.cfm
- HQ State/Province: New York
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Small Cap/Growth
- Next Earnings Release: Aug. 02, 2019
- Last Earnings Release: May. 08, 2019
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH. Intercept owns worldwide rights to OCA outside of China, where it has licensed out the product to Sumitomo Dainippon Pharma.
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 83.03 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| SMZCX | AlphaCentric Small Cap Opps C | 7.12% |
| CIG84024 | CI Global Health Sciences Corp Cl F4 | 5.87% |
| FBT | First Trust NYSE Arca Biotech ETF | 3.22% |
| VLLIX | Value Line Larger Companies Focus Instl | 2.86% |
| ETCHX | Eventide Healthcare & Life Sciences C | 2.37% |
| VLIIX | Value Line Capital Appreciation Instl | 2.32% |
| FRBRX | Franklin Biotechnology Discovery R6 | 1.27% |
| RYJ | Invesco Raymond James SB-1 Equity ETF | 0.67% |
Excel Add-In Codes
- Name: =YCI("ICPT","name")
- Description: =YCI("ICPT","description")
- Sector: =YCI("ICPT","sector")
- Industry: =YCI("ICPT","industry")
- Est. Current Fiscal Year End: =YCI("ICPT","fye")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- ICPT Tweets Stocktwits
Advertisement
